James Roger Mcilroy1,2, Niharika Nalagatla1, Richard Hansen3, Ailsa Hart4, Georgina Louise Hold1,5. 1. School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK. 2. EnteroBiotix Limited, Aberdeen, UK. 3. Royal Hospital for Children, Glasgow, UK. 4. IBD Unit, St Mark's Hospital, Harrow, UK. 5. Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: Interest in the use of faecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD) has increased following outcomes in patients with Clostridioides difficile infection (CDI). While research exploring clinician awareness and attitude towards the use of FMT in CDI has been carried out, data for IBD are currently lacking. OBJECTIVE: To assess the perceptions of gastroenterologists and current practice relating to FMT as a treatment for IBD in the UK. DESIGN: A web-based survey (Snap Survey software) was distributed through the British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition e-newsletters, and at the BSG Conference in June 2017. RESULTS: 61 respondents completed the survey including presubspecialty trainees, gastroenterology specialists, associate specialists and consultants. Most (95%; n=58) respondents stated that they had heard of FMT being used as a treatment for IBD prior to participating in the survey. Based on current evidence, 34% (n=21) of respondents would consider using FMT in patients with IBD, 26% (n=16) would not and 39% (n=24) were undecided. When asked to rank routes of delivery in terms of preference, nasogastric tube was the least preferred route (39%; n=24) and oral capsule was the most preferred route (34%; n=21). CONCLUSIONS: A clear majority of UK gastroenterologists recognise FMT as a potential treatment for IBD; however, uptake is limited. A proportion of clinicians would consider FMT in IBD and the majority would consider entering patients into clinical trials. Future work should explore the utility and efficacy of oral FMT capsules in IBD.
BACKGROUND: Interest in the use of faecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD) has increased following outcomes in patients with Clostridioides difficile infection (CDI). While research exploring clinician awareness and attitude towards the use of FMT in CDI has been carried out, data for IBD are currently lacking. OBJECTIVE: To assess the perceptions of gastroenterologists and current practice relating to FMT as a treatment for IBD in the UK. DESIGN: A web-based survey (Snap Survey software) was distributed through the British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition e-newsletters, and at the BSG Conference in June 2017. RESULTS: 61 respondents completed the survey including presubspecialty trainees, gastroenterology specialists, associate specialists and consultants. Most (95%; n=58) respondents stated that they had heard of FMT being used as a treatment for IBD prior to participating in the survey. Based on current evidence, 34% (n=21) of respondents would consider using FMT in patients with IBD, 26% (n=16) would not and 39% (n=24) were undecided. When asked to rank routes of delivery in terms of preference, nasogastric tube was the least preferred route (39%; n=24) and oral capsule was the most preferred route (34%; n=21). CONCLUSIONS: A clear majority of UK gastroenterologists recognise FMT as a potential treatment for IBD; however, uptake is limited. A proportion of clinicians would consider FMT in IBD and the majority would consider entering patients into clinical trials. Future work should explore the utility and efficacy of oral FMT capsules in IBD.
Authors: Sudarshan Paramsothy; Michael A Kamm; Nadeem O Kaakoush; Alissa J Walsh; Johan van den Bogaerde; Douglas Samuel; Rupert W L Leong; Susan Connor; Watson Ng; Ramesh Paramsothy; Wei Xuan; Enmoore Lin; Hazel M Mitchell; Thomas J Borody Journal: Lancet Date: 2017-02-15 Impact factor: 79.321
Authors: Paul Moayyedi; Michael G Surette; Peter T Kim; Josie Libertucci; Melanie Wolfe; Catherine Onischi; David Armstrong; John K Marshall; Zain Kassam; Walter Reinisch; Christine H Lee Journal: Gastroenterology Date: 2015-04-07 Impact factor: 22.682
Authors: Stacy A Kahn; Ashley Vachon; Dylan Rodriquez; Sarah R Goeppinger; Bonnie Surma; Julia Marks; David T Rubin Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: M N Quraishi; J Segal; B Mullish; V L McCune; P Hawkey; A Colville; H Williams; A Hart; T H Iqbal Journal: J Hosp Infect Date: 2016-11-03 Impact factor: 3.926
Authors: Colleen R Kelly; Alexander Khoruts; Christopher Staley; Michael J Sadowsky; Mortadha Abd; Mustafa Alani; Brianna Bakow; Patrizia Curran; Joyce McKenney; Allison Tisch; Steven E Reinert; Jason T Machan; Lawrence J Brandt Journal: Ann Intern Med Date: 2016-08-23 Impact factor: 25.391